Patient-Reported Outcomes After Tetralogy of Fallot Repair

Cross-sectional study

J Am Coll CardiolPublished 16 May 2023

Study context

Population: Adolescents and adults with repaired tetralogy of Fallot (TOF) and moderate or greater pulmonary regurgitation46.3% female
Participants: 607 adolescents

Exposure: Age cohorts: <18, 18 to 25, 26 to 40, and >40 years
Outcome: PROs: QOL linear analogue scale (QOL-LAS) and HS visual analogue scale (HS-VAS)

As reported in the abstract

QOL-LAS and HS-VAS scores (0-100) by age cohort

Median QOL linear analogue scale (QOL-LAS) similar across age cohorts (<18, 18 to 25, 26 to 40, >40 years)

85, 80, 80, 80; P = 0.056

Median HS visual analogue scale (HS-VAS) lowest in the oldest cohort (>40 years)

77

Median HS-VAS in the 3 younger cohorts

85, 80, 80

HS-VAS: oldest vs 3 younger cohorts

P = 0.004

Observational data: associations, not effects.

Outcome	<18 years	18 to 25 years	26 to 40 years	>40 years
Poor mobility and pain or discomfort with advancing age
Poor mobility	Not reported in the abstract	Not reported in the abstract	Not reported in the abstract	19.1%
Pain or discomfort	Not reported in the abstract	Not reported in the abstract	Not reported in the abstract	37.2%

Poor mobility and pain or discomfort with advancing age — Increased poor mobility with advancing age: P < 0.001
Poor mobility and pain or discomfort with advancing age — Increased pain or discomfort with advancing age: P = 0.004

Factors associated with superior patient-reported outcomes (PROs) (multivariable regression)

Being White, nonsyndromic, employed, better LV function: P < 0.05
Asymptomatic status (functional class I) associated with the greatest number of quality of life (QOL) and health status (HS) measures: P < 0.001

Patient-Reported Outcomes After Tetralogy of Fallot Repair. J Am Coll Cardiol. Published 16 May 2023. doi:10.1016/j.jacc.2023.03.385

Summarised from the published abstract; every number is checked against it